SCHEMBL4021071

SCHEMBL4021071

O=C(O)c1cccc(N2CCN(Cc3ccccc3)CC2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.68
DRD3 P35462 1/20 0.68
DRD4 P21917 3/20 0.64
ALDH1A1 P00352 3/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
KDM4E B2RXH2 2/20 0.63
GAA P10253 1/20 0.63
HPGD P15428 1/20 0.63
HSD17B10 Q99714 1/20 0.63
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
HIF1A Q16665 1/20 0.61
LMNA P02545 1/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
HTR7 P34969 2/20 0.59
HTR1A P08908 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27040086 0.91 CYP2D6 (0.69) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL31593043 0.91 CYP2D6 (0.69) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL6428902 0.90 DRD2 (0.66) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL2323421 0.89 DRD2 (0.64) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL7388920 0.85 ALDH1A1 (0.65) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL32688379 0.85 ALDH1A1 (0.80) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL17656753 0.84 ITGB3 (0.63) DRD2DRD3DRD4KDM4EHSD17B10
SCHEMBL1066467 0.84 HTR2A (0.72) DRD4ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL6707329 0.83 PRMT1 (0.67) DRD2DRD3DRD4ALDH1A1MEN1
SCHEMBL2710557 0.82 CYP2D6 (0.57) DRD2DRD3ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1082308-B1 HETEROCYCLICALLY SUBSTITUTED AMIDES USED AS CALPAIN INHIBITORS ABBOTT GMBH & CO KG (DE) 2009-04-01 EP disclosed
US-6562827-B1 For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages ABBOTT LABORATORIES 2003-05-13 US disclosed
EP-1082308-A1 HETEROCYCLICALLY SUBSTITUTED AMIDES USED AS CALPAIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-03-14 EP disclosed
WO-1999054305-A1 HETEROCYCLICALLY SUBSTITUTED AMIDES USED AS CALPAIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1999-10-28 WO disclosed